Physician profile
Anant Sharma
NPI 1154522209
$8,448.78
in general payments reported to CMS, 2019-2025
53 companies · $6,359 in 2025
The $6,359 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $17.18 · 2021: $177 · 2022: $212 · 2023: $77.16 · 2024: $1,491 · 2025: $6,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,581 · Consulting Fee: $2,560 · Long Term Medical Supply Or Device Loan: $1,446 · Travel and Lodging: $219 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,581.40 |
| Consulting Fee | $2,560.00 |
| Long Term Medical Supply Or Device Loan | $1,446.39 |
| Travel and Lodging | $218.88 |
| Education | $119.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $2,949.89 | 2025 | Imetelstat, Rytelo |
| Novartis Pharmaceuticals Corporation | $1,612.60 | 2023-2025 | |
| Incyte Corporation | $352.18 | 2023-2025 | Monjuvi, Jakafi, Monjuvi |
| Puma Biotechnology, INC. | $246.54 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $207.10 | 2025 | Enhertu, Calquence, Imfinzi |
| Pfizer INC. | $200.39 | 2019-2025 | |
| Celgene Corporation | $183.18 | 2022-2025 | Reblozyl, Opdualag |
| Genmab U.S., INC. | $180.14 | 2025 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $177.07 | 2019-2025 | Opdivo |
| Daiichi Sankyo INC. | $148.86 | 2021-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $129.70 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $121.41 | 2024-2025 | Fruzaqla, Iclusig, Ninlaro |
| Myriad Genetic Laboratories, INC. | $117.59 | 2022 | |
| Astellas Pharma US INC | $99.95 | 2025 | |
| Emd Serono, INC. | $79.08 | 2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $78.69 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $75.02 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Glaxosmithkline, LLC. | $73.98 | 2022-2025 | Ojjaara, Jemperli |
| Abbvie INC. | $73.23 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.63 | 2024-2025 | |
| Array Biopharma INC | $69.44 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.62 | 2024-2025 | Gilotrif |
| Dendreon Pharmaceuticals LLC | $67.47 | 2024-2025 | Provenge |
| Stemline Therapeutics INC. | $60.82 | 2025 | Orserdu |
| Genzyme Corporation | $60.63 | 2025 | |
| Genentech USA, INC. | $60.28 | 2025 | Tecentriq, Phesgo |
| Lilly USA, LLC | $53.35 | 2020-2025 | Verzenio, Jaypirca |
| Tempus Ai, INC | $49.14 | 2024 | |
| Legend Biotech USA INC. | $49.10 | 2025 | Carvykti |
| Kyowa Kirin, INC. | $48.55 | 2025 | |
| Sobi, INC | $48.41 | 2025 | |
| Beone Medicines USA, INC. | $47.43 | 2025 | Tevimbra |
| Adc Therapeutics America, INC. | $47.17 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $46.85 | 2025 | |
| Karyopharm Therapeutics INC. | $45.88 | 2025 | Xpovio |
| Intuitive Surgical, INC. | $37.48 | 2024 | |
| Alnylam Pharmaceuticals INC. | $36.38 | 2025 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $35.26 | 2025 | Libtayo |
| Servier Pharmaceuticals LLC | $32.77 | 2025 | |
| Rigel Pharmaceuticals, INC. | $29.77 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Amgen INC. | $29.64 | 2025 | Lumakras, Imdelltra (Amg757) |
| Sumitomo Pharma America, INC. | $27.21 | 2025 | Orgovyx |
| Pharmacosmos Therapeutics INC. | $26.14 | 2025 | Monoferric |
| Tersera Therapeutics LLC | $25.23 | 2025 | Zoladex |
| Eisai INC. | $25.15 | 2024 | |
| Jazz Pharmaceuticals INC. | $24.88 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $22.36 | 2025 | Onivyde |
| Kite Pharma, INC. | $18.81 | 2024 | Yescarta |
| Sirtex Medical INC | $17.72 | 2025 | Sir-Spheres Microspheres |
| Caris Mpi, INC. | $17.60 | 2025 | Mi Cancer Seek |
| Acrotech Biopharma INC. | $17.49 | 2025 | Beleodaq |
| Agios Pharmaceuticals, INC. | $13.27 | 2024 | |
| Pharmaessentia USA Corporation | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anant Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.